Scholar Rock Holding (SRRK) Interest Expenses (2017 - 2026)
Scholar Rock Holding's (SRRK) quarterly Interest Expenses came in at $2.4 million in Q1 2026, up 15.46% year-on-year from $2.1 million in Q1 2025, and up 112.57% quarter-over-quarter from $1.1 million in Q4 2025.
Scholar Rock Holding (SRRK) Interest Expenses (2017 - 2026) Analysis & Trends
Scholar Rock Holding's Interest Expenses history runs 10 years deep, the most recent figure standing at $2.4 million for Q1 2026.
- On a quarterly basis, Interest Expenses rose 15.46% year-over-year to $2.4 million in Q1 2026; TTM through Mar 2026 was $8.4 million, a 1.13% increase from a year earlier, with the FY2025 full-year figure at $185.5 million, down 36.69% from the prior year.
- Interest Expenses grew to $2.4 million in Q1 2026 per SRRK's latest filing, from $1.1 million in the prior quarter.
- Across five years, Interest Expenses topped out at $159.6 million in Q3 2025 and bottomed at $748000.0 in Q2 2022.
- The 5-year median for Interest Expenses is $2.4 million (2026), against an average of $20.5 million.
- Across the five-year window, Interest Expenses tumbled 98.4% in 2022 and soared 5280.62% in 2025, its largest moves.
- Year by year, Interest Expenses stood at $1.3 million in 2022, then advanced by 23.58% to $1.7 million in 2023, then soared by 72.71% to $2.9 million in 2024, then sank by 61.05% to $1.1 million in 2025, then soared by 112.57% to $2.4 million in 2026.
- Per Business Quant, the three latest SRRK Interest Expenses figures stand at $2.4 million (Q1 2026), $1.1 million (Q4 2025), and $159.6 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -42,141.15 |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 100,000.00 |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 32.89 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 420.30 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 28.30 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 1.17 Bn |
| 10 | Scholar Rock Holding | 6.10 Bn | 6.10 Bn | - | 2.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.37 Mn |
| Mar 31, 2026 | 2.37 Mn |
| Dec 31, 2025 | 1.11 Mn |
| Dec 31, 2025 | 1.11 Mn |
| Sep 30, 2025 | 159.64 Mn |
| Sep 30, 2025 | 159.64 Mn |
| Jun 30, 2025 | 155.14 Mn |
| Jun 30, 2025 | 155.14 Mn |
| Mar 31, 2025 | 2.05 Mn |
| Mar 31, 2025 | 2.05 Mn |
| Dec 31, 2024 | 2.86 Mn |
| Dec 31, 2024 | 2.86 Mn |
| Sep 30, 2024 | 2.97 Mn |
| Sep 30, 2024 | 2.97 Mn |
| Jun 30, 2024 | 3.53 Mn |
| Jun 30, 2024 | 3.53 Mn |
| Mar 31, 2024 | 1.73 Mn |
| Mar 31, 2024 | 1.73 Mn |
| Dec 31, 2023 | 1.66 Mn |
| Dec 31, 2023 | 1.66 Mn |